

LUTRONIC WEEKLY REPORT

2018.07.09~2018.07.13

Lutronic News

✓ Lutronic; “Accucurve”, a non-invasive device for waist circumference reduction and pain reduction, secured MFDS approval. → [Lutronic’s laser “Accucurve” secured MFDS approval.](#) (Financial News/ July 11)

Korean Stock Market News


✓ With the introduction of the stewardship code (institutional investor’s fiduciary responsibility), decisions on entrusted assets are left to asset management companies so that so that institutional investors do not exercise excessive influence on them while strengthening voting rights. → [National Pension Fund is to leave over half of the voting rights to the entrusted asset management company.](#) (Seoul Economy/ July 9)

Industry News

✓ CUTERA announced today the appointment of Mr. Jason Richey to the newly created position of Chief Operating Officer (“COO”).Immediately prior to joining Cutera, Mr. Richey served as President of North America for LivaNova, PLC, a \$5 billion global medical device manufacturer headquartered in London, with a presence in more than 100 countries worldwide. → [Cutera \(CUTR\) Announces Jason Richey as COO](#) (StreetInsider/July 9)

✓ Hologic's Cynosure division announced today the North American launch of TempSure™ Vitalia, an FDA-cleared and Health Canada-approved advanced radiofrequency treatment.→ [Hologic's Cynosure Division Launches TempSure™ Vitalia In North America](#)(MarketInsider/ July 11)

STOCK PERFORMANCE



9.25% of shares (common stock) held by Foreign Investors as of July 13

MOHW notice:**“R:GEN-leveraged SRT in institutions approved.”**

CSC treatment using R:GEN is to be offered with no reimbursement.
The institutions can be checked on the MOHW home page.

Lutronic's selective retina therapy (SRT) using R:GEN will become available in hospitals and clinics. SRT is to be offered as a non-reimbursable procedure in medical institutions, as the Ministry of Health and Welfare (MOHW) releases a "limited approval" notice on SRT.

Lutronic said on July 13 that MOHW released a notice on the medical institutions where SRT using R:GEN will be offered. The institutions where SRT is available can be found on the MOHW website (<http://www.mohw.go.kr>). The designated institutions will be allowed to perform non-reimbursement procedures for patients with central serous chorioretinopathy (CSC).

"Once the contract with the medical institutions is completed, relevant patients will be able to receive the treatment," an official from Lutronic said. "As many clinicians are interested in SRT, we expect to see further notifications of other medical institutions.," he explained. "Several major hospitals are currently in the process of applying to use this medical technology," he added.

"SRT" is selective retina therapy using R:GEN, Korea's first retina treatment laser. R:GEN selectively affects only the retinal pigment epithelium (RPE) layer while leaving the overlying retinal layers intact, thereby treating the target disease by inducing regeneration of the normal RPE layer. It has proven its validity with 44 patents and 46 related papers so far. Safety of the treatment technique has also been secured by adopting real-time feedback (RTF) technology. This product has been approved for diabetic macular edema (DME) and CSC treatment in Korea and Europe.

For health technologies which are at the research stage, and for those technologies that have been proven to be safe and for which a clinical trial is deemed necessary, limited approval for non-reimbursement treatment is given based on the new health technology assessment process. This will enable the company to seize the opportunity to create clinical evidence and patients can benefit from non-reimbursable procedures. Since the "Regulation on Limited Approval based on new Health Technology Assessment and Implementation" was first introduced in 2014, an amendment was added in November 2016 to improve benefits by better reflecting the reality. With the amendment, the application scope has been expanded to include those medical technologies first developed in Korea and expansion of promising medical technologies with clinical effects is confidently expected.